![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sarossa | LSE:SARS | London | Ordinary Share | JE00BKWBZV64 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.52 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSARS
RNS Number : 9270S
Sarossa PLC
30 September 2014
Sarossa Plc
Annual Report and Financial Statements 2014
30 September 2014
AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2014
Sarossa Plc ("Sarossa" or the "Company) announces its audited financial results for the year ended 30 June 2014.
Highlights:
- Net assets at 30 June 2014 of GBP17.22 million (2013: GBP13.53 million).
- Profit after tax of GBP3.69 million (2013: GBP0.62 million) inclusive of an exceptional release of a legacy biotechnology provision of GBP1.60 million (2013: GBPnil).
- Operating profit before exceptional items of GBP2.08 million (2013: GBP 0.46 million).
- Portfolio investments at 30 June 2014 valued at GBP10.62 million represented by 4 AIM quoted holdings (2013: GBP7.61 million represented by 3 quoted holdings).
- Spend on new investments at cost of GBP1.09 million (2013: GBP6.65 million).
- Re-organisation into a Jersey, Channel Islands, based group under a new Jersey holding company, Sarossa Plc.
Michael Bretherton, Chairman, said:
"We remain committed to deliver additional value for our shareholders and will continue to maintain a rigorous and highly selective investment approach with a view to exploiting opportunities as they emerge. We are confident that this approach will enable us to build considerable value for shareholders going forward."
A letter will shortly be posted to shareholdersadvising that a full copy of the Company's Annual Report 2014 is now available on the Company's website at www.sarossaplc.com under the Investor Centre/Financial Reports section and that this contains on page 36, a Notice of the Annual General Meeting to be held at 11.00 a.m. on 20 November 2014 at the Company's registered office at 17 The Esplanade, St Helier, Jersey, JE2 3QA.
Enquiries :
Sarossa Plc
Mike Bretherton, Chairman 01534 719760
WH Ireland Limited (Nominated adviser)
Chris Fielding, Head of Corporate Finance 020 7220 1650
Chairman's Statement
The Group delivered a profit after tax for the year ended 30 June 2014 0f GBP3.69 million compared to a profit of GBP0.62 million in the previous year. That profit included an exceptional release of a legacy biotechnology provision of GBP1.60 million (2013: GBPnil). Operating profit before exceptional items was GBP2.08 million (2013: GBP0.46 million) and the increase of GBP1.62 million mainly reflects further revaluation gains amounting to GBP1.08 million on portfolio investments, together with an additional gain of GBP0.68 million on a derivative trading asset.
Antisoma Plc changed its name to Sarossa Capital Plc on 1 November 2013 in order to reflect the fact that it no longer has operations in biotechnology development and is now an investment and management company.
Sarossa Capital Plc subsequently completed a successful re-organisation into a Jersey, Channel Islands, based Group under which the former parent company became a wholly owned subsidiary of a new Jersey holding company, Sarossa Plc ('Sarossa' or 'the Company'), which was admitted to AIM on 2 May 2014. The business operation, assets and liabilities of the Sarossa Group immediately after the re-organisation were no different from those immediately before the re-organisation.
During the year, the Group spent GBP1.09 million on the purchase of additional portfolio investments. This spend comprised of a follow on investment in Silence Therapeutics Plc and also an investment in GVC Holdings Plc, undertaken in conjunction with the close out of an existing financial derivative position in that GVC stock.
The Company holds currently 4 portfolio investments, all of which are quoted on AIM, and for which the carrying value at 30 June 2014 was GBP10.62 million (30 June 2013: GBP7.61 million represented by 3 quoted holdings).
The Group continues to benefit from a strong balance sheet with cash and short term deposit balances of GBP6.13 million at 30 June 2014 compared to cash and short term deposit balances of GBP6.87 million at the previous 30 June 2013 year end. Net assets at 30 June 2014 were GBP17.22 million compared with GBP13.53 million at 30 June 2013.
Sarossa is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation. The Company is mainly focused on portfolio businesses with product and service platforms targeting major international markets through customers and partners with an international profile.
Investment portfolio update
An overview of the activities of the portfolio businesses in which Sarossa has a holding of over 3 per cent. is given below:
Silence Therapeutics Plc ('Silence'), which is AIM listed, is a global leader in the discovery, development and delivery of novel RNAi therapeutics for the treatment of serious diseases. The core technology of Silence is its proprietary form of a short interfering RNA molecule, known as AtuRNAi, that enables the development of novel molecular entities that "silence" or inactivate the genes expressed in some diseases. Additionally, the company has developed technology that preferentially delivers AtuRNAi to the vascular endothelium (AtuPLEX), the lung endothelium (DACC) and the liver (DBTC). ATU027 is the company's leading Oncology product and the company achieved a further key milestone during the last year by completing recruitment for a Phase 2a trial for Atu027 in combination with gemcitabine for pancreatic cancer. Another key target was achieved in April 2014 when Silence confirmed successful gene knockdown in non-human primates using its RNAi lung delivery system, DACC. The company has a robust IP estate protecting its proprietary technology and also has a sound balance sheet with net cash and deposits at 30 June 2014 of GBP26.3m. Sarossa' s shareholding at 30 June 2014 was, and continues to be, 4.65 per cent. of the issued share capital of Silence.
Plant Health Care Plc ('PCH') which is AIM listed, is a leading provider of novel patent protected biological products to the global agriculture markets. The company has a portfolio of established products based on its proprietary Harpin and Myconate(R) technologies. PHC's products increase crop yields by enhancing natural processes within the plant. In 2013, the company signed a development and commercialisation agreement with Arysta LifeScience for the foliar use of Harpin <ALPHA><BETA> in several crops, in a number of geographies. The first fruit of that collaboration was the US launch in 2014 of "Astera(TM) with <ALPHA><BETA>pro(TM)", a mixture of Harpin <ALPHA><BETA> with the fungicide propiconazole. Development work on other products and territories continues with Arysta LifeScience. PHC is also continuing to seek other commercial agreements for both Harpin <ALPHA><BETA> and Myconate with other agricultural majors and has an active pipeline of negotiations. PHC anticipates completing at least one additional commercial agreement during the remainder of 2014. Sarossa's holding in PCH at 30 June 2014 was, and continues to be, 4.72 per cent.
In addition to the above, Sarossa has holdings of below 3 per cent. in two profitable AIM listed companies, one of which operates in the online gaming and sports betting markets and the other is a care sector support services business. Both of these companies have solid dividend yield and favourable growth records.
Outlook
There is continued reason for investment caution in the near term, given the many threats to a sustained global recovery, including the crises in Ukraine and the Middle East, Europe's continuing debt problems and the slowing down of Federal Reserve bond purchases in the US. We remain committed, however, to deliver additional value for our shareholders and will continue to maintain a rigorous and highly selective investment approach with a view to exploiting opportunities as they emerge. We are confident that this approach will enable us to build considerable value for shareholders going forward.
Michael Bretherton
Chairman
30 September 2014
Consolidated Statement of Comprehensive Income for the year ended 30 June 2014
2014 2013 GBP'000 GBP'000 -------- -------- Gain on portfolio investments 1,816 133 Other income 594 644 ----------------------------------------------- -------- -------- Portfolio return and revenue 2,410 777 Research and development credit/(expenditure) 6 (6) Release of legacy biotechnology provision 1,603 - Administrative expenses (333) (310) ----------------------------------------------- -------- -------- Operating profit 3,686 461 ----------------------------------------------- -------- -------- Analysed as: Operating profit before exceptional items 2,083 461 Exceptional items 1,603 - ----------------------------------------------- -------- -------- Operating profit 3,686 461 Finance income 47 170 Finance expense (43) (9) ----------------------------------------------- -------- -------- Profit before taxation 3,690 622 Taxation - - -------- -------- Profit for the year 3,690 622 ----------------------------------------------- -------- -------- Earnings per ordinary share Basic 0.58p 0.10p ----------------------------------------------- -------- -------- Diluted 0.58p 0.10p ----------------------------------------------- -------- --------
There are no other items of comprehensive income.
Consolidated Statement of Changes in Equity as at 30 June 2014
Retained earnings Share capital Share premium Merger reserve Other reserve deficit Total GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 --------------------- -------------- -------------- --------------- -------------- -------------------- -------- At 1 July 2012 10,725 122,091 - 8,282 (128,186) 12,912 Total comprehensive income for the year - - - - 622 622 At 30 June 2013 10,725 122,091 - 8,282 (127,564) 13,534 --------------------- -------------- -------------- --------------- -------------- -------------------- -------- Total comprehensive income for the year - - - - 3,690 3,690 Group re-organisation (4,331) (122,091) 126,422 (8,282) 8,282 - At 30 June 2014 6,394 - 126,422 - (115,592) 17,224 --------------------- -------------- -------------- --------------- -------------- -------------------- --------
Consolidated Statement of Financial Position at 30 June 2014
2014 2013 GBP'000 GBP'000 ----------------------------- ---------- ---------- ASSETS Non-current assets Portfolio Investments 10,624 7,606 ---------- ---------- 10,624 7,606 ----------------------------- ---------- ---------- Current assets Trade and other receivables 594 697 Derivative trading assets - 170 Short-term deposits 2,603 1,500 Cash and cash equivalents 3,530 5,367 6,727 7,734 ----------------------------- ---------- ---------- Total assets 17,351 15,340 ----------------------------- ---------- ---------- LIABILITIES Current liabilities Trade and other payables (127) (96) Provisions - (1,710) ----------------------------- ---------- ---------- Total liabilities (127) (1,806) ---------- ---------- Net current assets 6,600 5,928 ----------------------------- ---------- ---------- Net assets 17,224 13,534 ----------------------------- ---------- ---------- Shareholders' equity Share capital 6,394 10,725 Share premium - 122,091 Merger reserve 126,422 - Other reserves - 8,282 Retained earnings deficit (115,592) (127,564) ---------- ---------- Total shareholders' equity 17,224 13,534 ----------------------------- ---------- ----------
Consolidated Statement of Cash Flows for the year ended 30 June 2014
2014 2013 GBP'000 GBP'000 -------- -------- Cash flows from operating activities Profit before tax 3,690 622 Adjustments for: Foreign exchange (gains)/losses (48) 94 Release of legacy biotechnology provision (1,603) - Finance income (47) (170) Unrealised gain on revaluation of portfolio investments and derivative assets (1,763) (85) ------------------------------------------------------------------------------- -------- -------- Operating cash inflows before movement in working capital 229 461 Purchase of portfolio investments (1,085) (6,648) Decrease / (increase) in trade and other receivables 87 (21) Increase in trade and other payables 31 8 ------------------------------------------------------------------------------- -------- -------- Cash used in operations (738) (6,200) Interest received 47 170 ------------------------------------------------------------------------------- -------- -------- Net cash used in operating activities (691) (6,030) ------------------------------------------------------------------------------- -------- -------- Cash flows from investing activities (Increase)/reduction of short-term deposits with banks (1,103) 1,600 ------------------------------------------------------------------------------- -------- -------- Net cash (used)/generated from investing activities (1,103) 1,600 ------------------------------------------------------------------------------- -------- -------- Net increase in cash and cash equivalents (1,794) (4,430) Exchange losses on cash balances (43) (9) Cash, cash equivalents at beginning of year 5,367 9,806 ------------------------------------------------------------------------------- -------- -------- Cash and cash equivalents at end of year 3,530 5,367 ------------------------------------------------------------------------------- -------- -------- Short term deposits at end of year 2,603 1,500 ------------------------------------------------------------------------------- -------- -------- Cash, cash equivalents and short term deposits at end of year 6,133 6,867 ------------------------------------------------------------------------------- -------- --------
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR LLFVDADIAFIS
1 Year Sarossa Chart |
1 Month Sarossa Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions